Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic · Delayed-release tablet · Updated Nov 11, 2026

Valproate 250 mg delayed-release tablet price what pharmacies pay, and what you should

Pharmacies pay$2.54for 30 tablets · $0.0847 per tablet
Fair cash price$13.42cost + 15% + $10.50 fee
-1.1% in 4 weeks-10.6% in a yearLast change Oct 21, 2026: pharmacies' invoice prices changed (survey)

Is my price fair?

Check the price you were quoted

Type what the pharmacy asked for valproate 250 mg delayed-release tablet and see the markup over what they pay.

How many?
$
Pharmacies payNADAC this week$2.54
Online cost-pluscost + 15% + fees$12.92
Fair cash pricecost + 15% + $10.50 fee$13.42
Your quotetype it above-
Pharmacies pay about $2.54 for 30 tablets. A fair cash price is around $13.42. Type your quote to see your markup.

A benchmark from public data, not a price offer or medical advice. Prices vary by pharmacy, insurance and discount programs.

Valproate 250 mg price history

What pharmacies pay for 30 tablets, weekly
$2.49$2.64$2.78$2.93DecFebAprJunAugOct
What pharmacies paid for 30 tablets of valproate 250 mg delayed-release tablet over 52 weeks: from $2.84 on Nov 12, 2025 to $2.54 on Nov 11, 2026.
Now
$2.54
52-week low
$2.54
52-week high
$2.88
A year ago
$2.84

Why the price changed

EffectiveBeforeAfterChangeReason
Oct 21, 2026$0.0856$0.0847-1.1%pharmacies' invoice prices changed (survey)
Sep 23, 2026$0.0851$0.0856+0.7%pharmacies' invoice prices changed (survey)
Aug 19, 2026$0.0851$0.0851-0.1%pharmacies' invoice prices changed (survey)
Jul 22, 2026$0.0863$0.0851-1.3%pharmacies' invoice prices changed (survey)
Jun 17, 2026$0.0892$0.0863-3.3%pharmacies' invoice prices changed (survey)
May 20, 2026$0.0867$0.0892+2.9%pharmacies' invoice prices changed (survey)
Apr 22, 2026$0.0863$0.0867+0.5%pharmacies' invoice prices changed (survey)
Mar 18, 2026$0.0858$0.0863+0.6%pharmacies' invoice prices changed (survey)

Prices per tablet. Reasons are the ones the national survey gives: a survey rate change comes from pharmacies' own invoices; a published price change follows the maker's list price.

What did you pay for valproate 250 mg delayed-release tablet? Share it.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Supply status: shortages & recalls

In shortage2 products are short or being discontinued
1 ongoing recall10 recalls on record, latest Jul 29, 2026

Shortages

  • Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)Fresenius Kabi USA, LLC · Unavailable · Reason: Demand increase for the drug · Updated Nov 3, 2026Next release November 2026. Check wholesalers for inventory.
  • Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)Hikma Pharmaceuticals USA, Inc. · Available · Updated Oct 14, 2026Additional lots will be available. Product will be made available as it is released.

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

Showing the 6 most relevant of 10 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

Every manufacturer and package code

21 companies sell valproate 250 mg delayed-release tablet under 68 package codes (NDCs). Pharmacies pay the same per tablet whichever maker they buy from - the national average is set for the generic as a group.

All 68 package codes
60687-868-01American Health Packaging71610-031-60Aphena Pharma Solutions...50090-1123-0A-S Medication Solutions50090-1123-1A-S Medication Solutions50090-2007-0A-S Medication Solutions50090-2007-1A-S Medication Solutions50090-7763-0A-S Medication Solutions50090-7763-1A-S Medication Solutions17856-0797-1Atlantic Biologicals Corp.69452-434-20Bionpharma Inc.69452-434-30Bionpharma Inc.68001-473-00BluePoint Laboratories68001-473-03BluePoint Laboratories71335-0008-1Bryant Ranch Prepack71335-0008-2Bryant Ranch Prepack71335-0008-3Bryant Ranch Prepack71335-0008-4Bryant Ranch Prepack71335-2277-1Bryant Ranch Prepack71335-2277-2Bryant Ranch Prepack71335-2277-3Bryant Ranch Prepack71335-2277-4Bryant Ranch Prepack71335-2783-1Bryant Ranch Prepack71335-2783-2Bryant Ranch Prepack71335-2783-3Bryant Ranch Prepack71335-2783-4Bryant Ranch Prepack71335-2783-5Bryant Ranch Prepack71335-2862-1Bryant Ranch Prepack71335-2885-1Bryant Ranch Prepack72162-2316-1Bryant Ranch Prepack72162-2316-5Bryant Ranch Prepack72162-2460-1Bryant Ranch Prepack72162-2460-3Bryant Ranch Prepack72162-2460-5Bryant Ranch Prepack67046-1571-3Coupler LLC67046-1683-3Coupler LLC72189-636-60Direct_Rx0904-6860-61Major Pharmaceuticals51655-365-52Northwind Health Company...68071-3553-6NuCare Pharmaceuticals,In...72789-353-01PD-Rx Pharmaceuticals...68788-4079-3Preferred Pharmaceuticals...68788-4079-6Preferred Pharmaceuticals...68788-4079-9Preferred Pharmaceuticals...68788-8609-3Preferred Pharmaceuticals...68788-8609-6Preferred Pharmaceuticals...68788-8609-9Preferred Pharmaceuticals...82804-233-30Proficient Rx LP70518-3055-1Remedyrepack Inc.70518-3055-3Remedyrepack Inc.70518-3055-5Remedyrepack Inc.70518-3055-6Remedyrepack Inc.70518-3055-7Remedyrepack Inc.70518-3431-0Remedyrepack Inc.70518-3431-2Remedyrepack Inc.57237-047-01Rising Pharma Holdings...57237-047-05Rising Pharma Holdings...60760-698-60St. Mary's Medical Park...62756-797-13Sun Pharmaceutical...62756-797-88Sun Pharmaceutical...29300-139-01Unichem Pharmaceuticals...29300-139-05Unichem Pharmaceuticals...0832-7123-01Upsher-Smith Laboratories...0832-7123-11Upsher-Smith Laboratories...0832-7123-15Upsher-Smith Laboratories...00832-7123-89no longer listed60687-0868-11no longer listed68084-0776-01no longer listed68084-0776-11no longer listed

4 older package codes are still priced but no longer in the current FDA listing.

A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.

The brand costs 48x more

This generic$2.5430 tablets
Depakote (brand)$121.26same amount

Make sure your prescription is filled with the generic unless your prescriber wrote "brand medically necessary".

Questions to ask your pharmacist

  1. "Am I being charged for the generic or the brand?" The brand costs pharmacies up to $121.26 for the same amount.
  2. "What is your cash price, without insurance?" For low-cost generics it can be less than a copay.
  3. "Is a 90-day supply cheaper per tablet?" Dispensing fees are charged per fill, so fewer fills often cost less.
  4. "Would 125 mg delayed-release tablet work for me instead?" Pharmacies pay $0.0532 per tablet for it, against $0.0847 for this one. Only your prescriber can say whether a different strength or form suits you.
  5. "Do you match other pharmacies or accept discount cards?" Many do, if you ask.

These are questions, not advice. Never change how you take a medicine without talking to your prescriber or pharmacist.

Other valproate strengths and forms

Strength and formPer unitPharmacies pay4 weeks52 weeks
250 mg capsule$0.2422$7.27 / 30 capsules-0.2%-3.1%
125 mg delayed-release capsule$0.1971$5.91 / 30 capsules-1.8%-9.8%
125 mg delayed-release tablet$0.0532$1.60 / 30 tablets-3.2%-3.9%
500 mg delayed-release tablet$0.1561$4.68 / 30 tablets-2.9%-0.7%
250 mg (24 hr) extended-release tablet$0.1386$4.16 / 30 tablets+6.7%-0.2%
500 mg (24 hr) extended-release tablet$0.1957$5.87 / 30 tablets+0.7%+6.9%
100 mg/mL, 5 mL injectionNot priced this week
50 mg/mL oral solution$0.0335$6.71 / 200 mL+1.2%+3.3%

Official label & what changed

Last changedDecember 12, 2025
Version18 of 18
EffectiveDec 11, 2025
Read the label

These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE TABLETS. DIVALPROEX SODIUM delayed-release tablets, for oral use Initial U.S. Approval: 1983

This drug has a boxed warning

WARNING: LIFE THREATENING ADVERSE REACTIONS

WARNING: LIFE THREATENING ADVERSE REACTIONS

See full prescribing information for complete boxed warning.

Hepatotoxicity, including fatalities, usually during the first 6 months of treatment. Children under the age of two years and patients with mitochondrial disorders are at higher risk. Monitor patients closely, and perform serum liver testing prior to therapy and at frequent intervals thereafter (

5.1)

Fetal Risk, particularly neural tube defects, other major malformations, and decreased IQ (

5.2,

5.3,

5.4)

Pancreatitis, including fatal hemorrhagic cases (

5.5)

Hepatotoxicity

General Population:Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months

[see

Warnings and Precautions (5.1)]

.

Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. When divalproex sodium delayed-release tablets are used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.

Patients with Mitochondrial Disease:There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase

γ

(POLG) gene (e.g. Alpers-Huttenlocher Syndrome). Divalproex sodium delayed-release tablets are contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder

[see

Contraindications (4)]

. In patients over two years of age who are clinically suspected of having a hereditary mitochondrial disease, divalproex sodium delayed-release tablets should only be used after other anticonvulsants have failed. This older group of patients should be closely monitored during treatment with divalproex sodium delayed-release tablets for the development of acute liver injury with regular clinical assessments and serum liver testing. POLG mutation screening should be performed in accordance with current clinical practice

[see

Warnings and Precautions (5.1)]

.

Fetal Risk

Valproate can cause major congenital malformations, particularly neural tube defects (e.g., spina bifida). In addition, valproate can cause decreased IQ scores and neurodevelopmental disorders following

in uteroexposure.

Valproate is therefore contraindicated for prophylaxis of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception

[see

Contraindications (4)]

. Valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.

Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. In such situations, effective contraception should be used

[see

Warnings and Precautions (5.2,

5.3,

5.4)]

.

A Medication Guide describing the risks of valproate is available for patients

[see

Patient Counseling Information (17)]

.

Pancreatitis

Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated

[see

Warnings and Precautions (5.5)]

.

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Questions about valproate 250 mg delayed-release tablet

How much does valproate 250 mg delayed-release tablet cost without insurance?

Pharmacies pay about $2.54 for 30 tablets ($0.0847 per tablet) as of November 11, 2026. A fair cash price is about $13.42: that cost plus a 15% margin and a $10.50 dispensing fee. Online cost-plus pharmacies charge around $12.92 including shipping.

Is my price for valproate 250 mg delayed-release tablet fair?

Compare it with the fair cash price of $13.42 for 30 tablets. Up to about $16.78 is fair; above $26.84 is high, and worth asking the pharmacy for its cash price or trying another pharmacy. Check your quote.

Is valproate 250 mg delayed-release tablet getting more expensive?

Over the last four weeks the price pharmacies pay fell 1.1%. Over a year it fell 10.6%. See the 52-week chart.

What is the brand name of valproate 250 mg delayed-release tablet?

Depakote 250 mg delayed-release tablet. The brand has the same active ingredient but costs pharmacies more.

Who makes valproate 250 mg delayed-release tablet?

21 companies: American Health Packaging, Bionpharma Inc., BluePoint Laboratories, Major Pharmaceuticals, Rising Pharma Holdings, Inc., Sun Pharmaceutical Industries, Inc., Unichem Pharmaceuticals (USA), Inc., Upsher-Smith Laboratories, LLC, Aphena Pharma Solutions - Tennessee, LLC, A-S Medication Solutions, Atlantic Biologicals Corp., Bryant Ranch Prepack and more. See every package code.

Is valproate in shortage?

Yes - 2 products are listed as short or being discontinued. Details.

Has valproate been recalled?

10 recalls on record, 1 ongoing. Recalls name specific lots - check yours.

What does "pharmacies pay" mean?

It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.

Talk about valproate 250 mg delayed-release tablet

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.